Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling

Victor Peperzak¹, Erik Slinger¹,², Johanna Ter Burg¹,² and Eric Eldering*,¹,³

For successful treatment of malignant B-cells it is crucial to understand intrinsic survival requirements in relation to their normal progenitors. Long-lived humoral immunity as well as most B-cell malignancies, originate in the germinal center (GC). Murine GC B-cells depend on pro-survival protein MCL-1, but not BCL-XL. In contrast, naive and memory B-cells depend on BCL-2, but not BCL-XL or MCL-1. For human B-cell subsets, the functional relationships among BCL-2 members are unclear, and also if and how they shift after malignant transformation. We here dissect these aspects in human tonsil and primary leukemia (CLL) cells by single and combined treatment with novel, highly specific BH3-mimetics. We found that MCL-1 expression in GC B-cells is regulated post-translationally and its importance is highlighted by preferential binding to pro-apoptotic BIM. In contrast, BCL-XL is transcriptionally induced and binds solely to weak sensitizer BIK, potentially explaining why BCL-XL is not required for GC B-cell survival. Using novel BH3-mimetics, we found that naive and memory B-cells depend on BCL-2, GC cells predominantly on MCL-1, whereas plasma cells need both BCL-XL and MCL-1 for survival. CLL cells switch from highly sensitive for BCL-2 inhibition to resistant after CD40-stimulation. However, combined inhibition of BCL-2, plus BCL-XL or MCL-1 effectively kills these cells, thus exposing a weakness that may be therapeutically useful. These general principles offer important clues for designing treatment strategies for B-cell malignancies.

Cell Death and Differentiation (2017) 24, 111–119; doi:10.1038/cdd.2016.105; published online 30 September 2016

The intrinsic apoptotic pathway is controlled by the BCL-2 protein family. Expression of the pro-survival members, namely BCL-2, BCL-XL, BCL-W, MCL-1, BFL-1 and BCL-B, varies greatly and strongly depends on the cell type, its environment and activation state.¹ Understanding the regulation and degree of expression is key to determine which pro-survival protein(s) is (are) essential for survival of certain cell types at different stages of differentiation or activation.

An important distinction can be made for the BCL-2 family. Although certain members can induce apoptosis by direct binding to effectors BAX and BAK (BIM, BID and P53 up-regulated modulator of apoptosis (PUMA); also referred to as activators), other members can only indirectly regulate apoptosis by sequestering pro-survival proteins (BAD, NOXA, BIK and so on; referred to as sensitizers).¹

Overexpression of pro-survival BCL-2 family members can allow survival of proliferating cells that would otherwise be deleted via apoptosis. As a consequence, oncogenic mutations that can arise in the germinal center (GC) combined with overexpression of pro-survival BCL-2 proteins, facilitates cancer development.¹,² BH3-mimetics were developed to block specific pro-survival BCL-2 proteins and force cells that depend on them to undergo apoptosis. BCL-2-specific BH3-mimetic ABT-199 (Venetoclax) has shown great promise in the treatment of chronic lymphocytic leukemia (CLL), as CLL cells uniformly over-express BCL-2.³ Like BCL-2, MCL-1 is often over-expressed in different B-cell malignancies, such as

1Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; ²Department of Hematology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands and ³Department of Lymphoma, Myeloma Center Amsterdam, LYMMCARE, Amsterdam, The Netherlands.

*Corresponding author: E Eldering, Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands. Tel: +31 20 566 7018; Fax: +31 20 566 9756; E-mail: e.eldering@amc.uva.nl

Abbreviations: BAD, Bcl-2 associated agonist of cell death; BAX, Bcl-2 antagonist/killer; BAK, Bcl-2-associated X; BBC3, Bcl-2-binding component 3; BCL-2, B-cell lymphoma 2; BCL2L11, B-cell lymphoma 2 like 11; BCL-B, B-cell lymphoma B; BCL-W, B-cell lymphoma W; BCL-XL, B-cell lymphoma extra-large; BCR, B-cell receptor; BFL-1, Bcl-2-related gene in fetal liver 1; BH3, Bcl-2 homology domain 3; BID, BH3-interacting domain death agonist; BIK, Bcl-2 interacting killer; BIM, Bcl-2 interacting mediator of cell death; BIMEL, Bcl-2 interacting mediator of cell death extra-long isoform; BIML, Bcl-2 interacting mediator of cell death long isoform; BIMS, Bcl-2 interacting mediator of cell death short isoform; BMF, Bcl-2 modifying factor; BN, Naive B cells; BTRC, Beta-transducin repeat containing; jTrCP1, Beta-transducin repeat containing E3 ubiquitin protein ligase pseudogene 1; CB, Centriols; CC, Centrocytes; CHX, Cycloheximide; CLL, Chronic lymphocytic leukemia; DZ, Dark zone; FACS, Fluorescence-activated cell sorting; FBW7 and FBXW7, F-Box and WD repeat domain-containing 7; FCRFudarabine, Cytoxaphosphamide and Rituximab; FL, follicular lymphoma; GC, Germinal center; Hprt, Hypoxanthine-guanine phosphoribosyltransferase; HUWE1, HECT UBA and WWE domain-containing 1; IP, Immunoprecipitation; LZ, Light zone; MCL-1, Myeloid cell leukemia 1; Mem, memory B cells; MLPA, Multiplex ligation-dependent probe amplification; Mule, Mcl-1 ubiquitinligase E3; NOXA, Latin for ‘damage’; OA, Okadac acid; PBS, Phosphate-buffered saline; PC, Plasma cells; PCR, Polymerase chain reaction; PP2A, Protein phosphatase 2; PUMA, P53 up-regulated modulator of apoptosis; RNA, Ribonucleic acid; RT-MLPA, Reverse transcriptase multiplex ligation-dependent probe amplification; TGF-β, Transforming growth factor beta

Received 11.4.16; revised 25.8.16; accepted 31.8.16; Edited by A Strasser; published online 30.9.16
diffuse large B-cell lymphoma, follicular lymphoma (FL), CLL and multiple myeloma. In addition to BCL-2-specific BH3-mimetics, novel BH3-mimetics have become available for in vitro use that specifically target MCL-1 (A-1210477) or BCL-XL (WEHI-539).

Most lymphomas derive from GC B cells or their descendants. Thus, predicting efficacy of BH3-mimetics in B-cell malignancies requires detailed insight into expression of BCL-2 family proteins, their interaction profile and sensitivity to BH3-mimetics in healthy B cells. High-level MCL-1, BCL-XL and reduced BCL-2 protein expression has been previously detected in the human and murine GC.10-13 In addition, transcriptional induction of BFL-1 was observed by gene expression profiling in the human and murine GC light zone (LZ).14 Although MCL-1 and BCL-XL proteins are both highly expressed in murine GC B cells, only MCL-1 appeared to be important for their survival.13 The divergent roles of MCL-1 and BCL-XL in GC B cells still remain unexplained, and it is unknown if this also holds for human B cells.

The aim of our current study is twofold; first, we aim to investigate the expression, regulation and dependence on pro-survival BCL-2 family members in healthy primary human B cells from the tonsil, including GC B cells (discriminating centroblasts (CB) from the GC dark zone (DZ) and centrocytes (CC) from the LZ), and plasma cells (PC). Second, BH3-profiling with peptides has been used to predict dependence on pro-survival BCL-2 family members. Here, we use another approach using BH3-mimetic compounds that have become available and selectively inhibit either BCL-2, BCL-XL or MCL-1. Recently, an innovative method, called mito-profing, has tested such novel BH3-mimetics and confirmed their selectivity and potency. To exploit potential differences in sensitivity between healthy and malignant B cells we also used primary CLL cells. These cells normally respond well to inhibition with ABT-199, but upregulate BCL-XL, MCL-1 and BFL-1 on stimulation via CD40, mimicking the protective lymph node microenvironment and making them resistant to ABT-199 and other conventional CLL drugs.17 CLL and BCL cells can therefore be used as a model to study the dependence of primary malignant B cells on expression of the different BCL-2 family members.

**Results**

**BCL-2 family members are highly differentially expressed in human B-cell subsets.** To examine gene expression of the different BCL-2 family members, B-cell subsets were isolated from human tonsil specimens and subjected to multiplex ligation-dependent probe amplification assay (MLPA) covering both pro-apoptotic and pro-survival members of the BCL-2 family (Figures 1a–c; Supplementary Figure 1). Tonsil B cells were separated into naive B cells, memory B cells, PC or GC B cells based on expression of IgD and CD38 using flow cytometry. GC B cells were further subdivided into CB or CC based on expression of chemokine receptor CXCR4 and cell size (Figure 1a). We confirmed mRNA expression of pro-survival members using more sensitive quantitative real time polymerase chain reaction (qPCR) (Figure 1d), which also allowed quantification of BCL-2 family expression in the small PC population isolated from the tonsil. Combined, this revealed that BCL2 gene expression was virtually shut down when B cells enter the GC reaction. In contrast, gene expression of BCLX and BFL1 was induced in the LZ of the GC, whereas gene expression of MCL1 was significantly increased in PC only (Figures 1b–d). Besides MCL1, a significant increase in BCLX gene expression was observed in PC (Figure 1d). The expression pattern in memory B cells was not significantly different than in naive B cells (Figures 1b–d). In addition to the differential regulation of pro-survival BCL-2 family members, we also observed significantly increased gene expression of pro-apoptotic members BIM, BID, PUMA and especially BIK when B cells enter the GC reaction (Figure 1; Supplementary Figure 2). Increased gene expression of these pro-apoptotic BCL-2 family members was also observed in PC (Supplementary Figure 3).

**Pro-survival BCL-2 proteins are transcriptionally regulated in tonsillar B cells, except MCL-1, that is regulated at the post-transcriptional level.** Protein expression of differentially expressed BCL-2 family members was monitored by western blot analysis on cells sorted as in Figure 1a. In general, gene expression was largely consistent with expression at the protein level (Figures 2a and b). Unlike BCLX and BFL1, increased MCL1 gene expression was not observed when B cells enter the GC reaction (Figures 1a–d). MCL-1 protein however is highly induced in GC B cells as measured by western blot and fluorescence microscopy (Figures 2a–c). Quantification of multiple experiments revealed that increased expression of MCL-1 and BCL-XL, or decreased expression of BCL-2, in GC B cells did not differ between CB or CC from the DZ or LZ, respectively (Figure 2b). Although induction of BFL-1 protein expression in CC seems to follow its regulation at the transcriptional level (Figures 1b–d and 2a), the currently available tools to detect BFL-1 protein did not allow quantification relative to naive B cells. In contrast to GC B cells, high-level MCL-1 protein expression was not observed in the T cell zone surrounding the tonsillar GC as observed by fluorescence microscopy (Figure 2c). Comparing MCL-1 protein expression to gene transcription suggested that MCL-1 protein stability is increased specifically in GC B cells (Figure 3a). Measuring MCL-1 protein turnover using translation inhibitor cycloheximide in highly purified naive B cells versus GC B cells indeed revealed that MCL-1 protein stability in GC B cells is strongly increased (Figure 3b; Supplementary Figures 4a and b). MCL-1 protein half-life is dictated by the combined action of a selection of specific kinases, phosphatases, deubiquitinases and ubiquitin ligases. Which of these players is responsible for the regulation of MCL-1 stability in GC B cells is currently unknown, although we did observe a significant decrease of known MCL-1-specific ubiquitin ligases in GC B cells (Figure 3c). In addition, we observed that inhibition of the protein phosphatase 2 (PP2A) complex using okadaic acid (OA) reduced MCL-1 stability in GC B cells (Figure 3d). The latter findings are in line with the observation that protein phosphatases, such as PP2A, are highly active in GC B cells.
Selective binding patterns of BCL-XL and MCL-1 in tonsillar B cells. To further probe the differential roles of MCL-1 and BCL-XL in tonsil B cells, we performed immunoprecipitation (IP) experiments to detect their binding partners. These IP experiments were performed on total B cells purified from the tonsil and this population consists mainly of GC B cells (CD38+; 36%), memory B cells (CD38−IgD−; 34%) and naive B cells (CD38−IgD+; 29%), with only a small fraction of PC (CD38++; 1.3%) (Supplementary Figure 5a). As protein expression of BCL-2, BCL-XL and MCL-1 in tonsil B cells is strictly cell-type specific (Figure 2b), with almost 90% of BCL-2 protein expressed in naive and memory B cells and over 80% of MCL-1 or BCL-XL protein expressed in GC B cells (Supplementary Figure 5), we deduced that IPs for MCL-1 or BCL-XL are mostly representative for GC B cells. These IP experiments revealed that MCL-1 was predominantly bound to BIM (Figure 4a) and not to other pro-apoptotic proteins such as BIK, PUMA or BID (Figure 4a). Expression of NOXA was barely detectable, but long exposures in some western blots did show a specific association with MCL-1, as expected based on the known specificity of NOXA (Supplementary Figure 6a). Aspecific bands in the IP fraction were visualized by incubation with labeled secondary antibodies only, indicated by stars (Figure 4a).

Extended running of the western blot containing IP fractions revealed that the BIMEL band was partly masked by an aspecific background band, but that in addition to BIM S and BIML, the BIMEL form is also associated with MCL-1 (Supplementary Figure 6a). BCL-XL, on the other hand, was not associated with BIM, but was associated with BIK instead, and no binding of BCL-XL to PUMA, BID or NOXA was detected (Figure 4a; Supplementary Figure 6a). MCL-1 IP could not completely deplete the total lysate of BIM, which either suggests saturation of the beads, or that part of the BIM protein pool was also associated with other proteins than MCL-1. BCL-2 IPs indeed showed that a small but detectable fraction of BIM was also bound to BCL-2. In addition to BIM, PUMA was found associated to BCL-2 (Supplementary
Figure 6b), whereas BIK was not bound to BCL-2 (Supplementary Figure 6c). As almost 90% of BCL-2 protein in the total B-cell lysate is derived from naive or memory B cells, these observed associations are also mostly reflective of these cell subsets. Thus, MCL-1 associates with BIM and NOXA and BCL-XL with BIK in GC B cells, whereas BCL-2 associates with PUMA and BIM in naive and/or memory B cells. Unfortunately, with the currently available BFL-1 antibodies, we were unable to successfully perform BFL-1 IPs to test a possible interaction of BIM or BIK to BFL-1. To test if the novel MCL-1-inhibitor A-1210477 could abrogate the interaction between MCL-1 and BIM, IP experiments were performed in the presence of A-1210477 and demonstrated a strong reduction of the interaction between MCL-1 and BIM (Figure 4b). Similarly, BCL-XL-BIK complexes could be dissociated using the BCL-XL-inhibitor WEHI-539 (Figure 4c). Combined, our data reveal a clear distinction in regulation as well as functional interactions between MCL-1 and BCL-XL in human tonsil B-cell subsets.

BH3-mimetic profiling reveals a divergent dependence on pro-survival BCL-2 family members in healthy B cells and exposes weaknesses in resistant leukemic B cells. In mouse models, expression of MCL-1 is essential for GC B-cell survival. The importance of MCL-1 expression for human B cells is currently unknown and was tested with A-1210477 by treating tonsil cells with different doses of the inhibitor, followed by flow cytometric determination of cell viability after gating on the different B cells subsets, as shown in Figure 1a. This revealed increased sensitivity of GC B cells and PC to inhibition of MCL-1 as compared with either naive or memory B cells (Figure 5a). A-1210477 is highly specific for MCL-1, although relatively high concentrations are necessary to displace BIM from MCL-1 and promote apoptosis. It can be expected that more potent inhibitors will reveal bigger differences in MCL-1 sensitivity between cell types in the future. Next, sensitivity to the BCL-XL-specific inhibitor WEHI-539 was tested in a similar manner. Although BCL-XL protein expression is strongly increased in GC B cells (Figures 2a and b), these cells are not sensitive to inhibition with WEHI-539 (Figure 5a). Importantly, this confirms earlier findings in mice in vivo, and is in line with BCL-XL binding to weak BH3 member BIK. PC in human tonsil are however sensitive to inhibition of BCL-XL (Figure 5a), in correlation with very high BCL-XL mRNA expression in PC (Figure 1d), and increased overall expression of BH3 members BIM, PUMA, BIK and BAD (Supplementary Figure 3). Finally, we tested dependence on BCL-2 exclusively using the BCL-2-specific inhibitor ABT-199. Comparable to mouse experiments using ABT-737, that
blocks both BCL-2 and BCL-XL naive and memory human B cells were highly sensitive to specific BCL-2 inhibition, whereas GC B cells and PC were not (Figure 5a). The differential sensitivities of tonsil subsets for the BH3-mimetics ranged from 10-fold (A-1210477) to >100-fold (WEHI-539, ABT-199).

**Figure 3** MCL-1 protein is stabilized in GC B cells. (a) Ratios of protein (average of quantified western blot experiments shown in Figure 2b, with n=2–4) over mRNA (average of real time qPCR experiments shown in Figure 1d, with n=3–5) in B-cell subsets for MCL-1, BCL-2 and BCL-XL expressed in arbitrary units (a.u.) (b) Western blot analysis on FACSP pure naïve or GC B cells for MCL-1 and Actin after culture for 0, 2 or 4 h (h) with cycloheximide (CHX), an inhibitor of protein synthesis. Data are representative of two individual experiments. (c) Real time qPCR of known MCL-1-specific ubiquitin ligases Mule (HUWE1), FBW7 (FBXW7) and μT RCP1 (BTRC) in purified cells as shown in Figure 1a, corrected for expression of household gene Hprt and relative to naïve B cells. Data are average of five experiments with S.E.M. Statistics were calculated in relation to Bn cells. (d) Western blot analysis on MACS-enriched GC B cells for MCL-1 and Actin after culture for 0, 2 or 4 h (h) with cycloheximide (CHX), with or without PP2A-inhibitor okadaic acid (OA). Cells in (b) and (d) were cultured in standard tissue culture medium (Iscove’s modified Dulbecco’s media) supplemented with 10% (v/v) heat-inactivated fetal calf serum and antibiotics, but without additional cytokines. *P≤0.05, **P≤0.01

**Figure 4** MCL-1 associates with BIM and BCL-XL associates with BIK in tonsil B cells. (a) Western blots after IP experiments in total B cells purified from the tonsil. Shown are the indicated proteins in the lysate after IP (cleared lysate) or the indicated proteins that were pulled down (IP). Background bands in the IP fraction were visualized by incubation with only the labeled secondary antibody and are indicated by (*). The experiment shown is representative of four individual experiments. (b) IP as in (a), but either with or without treatment of 30 μM A-1210477 for 4 h at 37 °C. Experiment is representative of two individual experiments. (c) IP as in (a), but either with or without treatment of 10 μM WEHI-539 for 4 h at 37 °C. Experiment is representative of two individual experiments.

**Role of pro-survival proteins in human B cells**
V Peperzak et al
Like GC B cells, CLL cells stimulated via CD40 have increased expression of BCL-XL, MCL-1 and BFL-1 when compared with unstimulated CLL cells that mainly express BCL-2.\textsuperscript{17,21} CLL cells can therefore be used as a model to study dependence of primary malignant B cells on expression of the different BCL-2 family members, with unstimulated CLL cells behaving as naive or memory B cells and CD40-stimulated CLL cells as GC B cells. However, in contrast to GC B cells, CLL cells do retain their high expression of BCL-2.\textsuperscript{17} As expected based on recent studies with ABT-199, CD40-stimulated CLL cells were insensitive to single treatment with specific BH3-mimetics (Figure 5b). However, different combinations of drugs were used to test potential additive or synergistic effects and revealed that ABT-199 plus WEHI-539 or ABT-199 plus A-1210477 efficiently induced apoptosis of CD40-stimulated CLL cells (Figure 5c).

**Discussion**

The maintenance of cancer cells is to a large extent controlled by the BCL-2-regulated or intrinsic apoptotic pathway. Targeting pro-survival BCL-2 family members using a novel class of therapeutics, called BH3-mimetics, can thus significantly improve the treatment of cancer.\textsuperscript{22} Although BH3-mimetic ABT-199 (Venetoclax) has been successfully used in clinical trials,\textsuperscript{20} there is still a lack of knowledge concerning the role and regulation of pro-survival BCL-2 proteins in healthy versus malignant B cells. Our expression analyses confirm transcriptional upregulation of BCLX and BFL1 in GC B cells,\textsuperscript{12,14} which seems to be induced in the GC LZ and may be induced on signaling via CD40 by T follicular helper cells in the LZ.

MCL-1 protein half-life is short in most cell types where it varies between 30 and 45 min,\textsuperscript{23–25} but conditions have been described for healthy\textsuperscript{26} and malignant\textsuperscript{27} T cells where proteasomal degradation of MCL-1 is inhibited, resulting in a prolonged protein half-life. Our transcriptional and protein analyses in purified cell populations demonstrate a significantly enhanced MCL-1 protein stability in the GC. As most B-cell malignancies originate in the GC, this observation is highly relevant and aberrant protein regulation of MCL-1 may underlie the observed overexpression in FL and diffuse large B-cell lymphomas.\textsuperscript{3,28} The down-regulation of MCL-1-specific ubiquitin ligases Mule, FBW7 and βTrCP1, as well as the impact of PP2A-inhibitor OA on MCL-1 degradation may...
suggest their involvement in regulation of MCL-1 stability. The exact mechanism(s) of altered MCL-1 protein stability in GC B cells is subject of ongoing studies, and may include differential activity of additional kinases, phosphatases, ubiquitin ligases and deubiquitinases. Our finding that PP2A may be involved in the regulation of MCL-1 protein stability in GC B cells is in line with earlier findings that describe highly increased activity of phosphatases in GC B cells specifically, including PP2A.

In addition to increased expression of BCL-XL, BFL-1 and MCL-1 in GC B cells, increased expression of pro-apoptotic BIM and BIK was also observed at both the mRNA and protein level and expression of both genes was already initiated in the DZ of the GC. BIK has been shown previously to be induced upon IgM ligation on B cells, and by transforming growth factor beta (TGF-β) in Burkitt lymphoma cell lines and GC cells. BIK may therefore be involved in selection of B cells in the GC. More recently it was shown that not only BIK, but also BIM and NOXA are up-regulated upon B-cell receptor (BCR) stimulation and that induction of all three is important for BCR-signaling-induced cell death. Thus, our findings show that the induction of pro-apoptotic BIM and BIK is countered by the induction of MCL-1 and BCL-XL in those cells that, at the moment of analysis, survived the selection process in the GC.

Our IP experiments performed with purified tonsil B cells revealed preferential binding of MCL-1 to BIM and of BCL-XL to BIK in GC B cells. These findings indicate that inhibition of MCL-1 releases BIM that is capable of inducing apoptosis by activating BAX and BAK, thereby explaining the central role for MCL-1 in human GC B cells. It also explains why inhibition of BCL-XL in GC B cells does not immediately result in apoptosis, as released BIK cannot directly activate BAX and BAK. Increased levels of free BIK may however sensitize GC B cells to other apoptotic stimuli. The latter may also be the case for PC that do seem to depend on BCL-XL expression. As PC highly express BIM and PUMA, in addition to BIK, it is unclear which BH3-only protein is the direct activator of WEHI-539-induced apoptosis. An alternative option is that in PC BCL-XL does bind to apoptotic activators such as BIM, BID or PUMA. As the percentage of PC in the tonsil is very small (Supplementary Figure 5a), the contribution of binding partners for BCL-XL in PC may not have been detected in our IP experiments. Previously, we found that in contrast to GC B cells, primary CLL cells do not express BIK, but highly express NOXA. In CLL, MCL-1 is bound to NOXA, whereas BIM is also bound to other pro-survival proteins such as BCL-2 and BCL-XL, in addition to MCL-1.

Thus, binding patterns of BCL-2 family members can vary between normal and malignant cell types and may cause differential sensitivity to specific BH3-mimetic drugs. The specificity of this approach was recently validated using specifically constructed cell lines, and was dubbed mito-priming. Our data using primary cells revealed that both GC B cells and tonsillar PC are significantly more dependent on MCL-1 expression than naive and memory B cells. In contrast, only PC are sensitive to inhibition of BCL-XL. Although long-lived PC in the BM do not depend on BCL-XL expression, newly generated PC and plasma blasts do. This supports the view that, as observed for platelets, BCL-XL acts as a survival timer for PC. BCL-XL expression induced during the GC reaction may protect PC en route to protective BM niches where local survival signals induce expression of MCL-1. As a large portion of tonsil PC are short-lived (multiple days instead of months to years for long-lived PC), dependence on BCL-XL fits with this hypothesis.

PC and GC B cells are highly insensitive to selective inhibition of BCL-2 using ABT-199, in contrast to naive and memory B cells. These findings are in line with experiments in mice where treatment with ABT-737 significantly reduces the naive and memory B-cell populations. Bfl-1/A1 promotes the survival of mature follicular B cells in mice and we observed increased expression of BFL-1 in human GC B cells. The current lack of BFL-1-specific inhibitors unfortunately precludes this type of BH3-mimetic profiling analysis in primary human B cells.

Combined, our experiments using healthy cells reveal a radical disparity in the expression of- and dependence on- pro-survival BCL-2 family members, which is schematically summarized in Figure 6. Naive and memory B cells mainly depend on BCL-2 expression for survival. GC B cells solely depend on expression of MCL-1, whereas PC in the tonsil require expression of both MCL-1 and BCL-XL. The abundance of MCL-1, BCL-2 or BCL-XL protein correlates well with the shifts in cellular dependence. Expression of MCL-1 in GC B cells is important for cell survival as it sequesters BIM, whereas expression of BCL-XL in these cells seems less important for survival as it is bound to BIK. Expression of BCL-2 in naive and memory B cells promotes cell survival through sequestration of PUMA and BIM.

CLL cells directly isolated from the blood efficiently underwent apoptosis on treatment with either ABT-199, less so for WEHI-539 or A-1210477, whereas CD40-stimulated CLL cells were significantly more resistant to all three compounds. The acquired resistance can be explained by the CD40-mediated induction of BCL-XL, MCL-1, BFL-1 and overexpression of BCL-2. BCL-XL contributes significantly to ABT-199 resistance as determined by knockdown experiments in primary CLL cells. In line with these findings, we show here that combined use of BH3-mimetics, especially the combination of ABT-199 plus WEHI-539 or ABT-199 plus A-1210477, induced apoptosis of stimulated CLL cells much more efficiently than single drug treatment. Synergistic effects of A-1210477 and ABT-263 (navitoclax), the orally bioavailable version of BCL-2- and BCL-XL-inhibitor ABT-737, have also recently been observed for multiple cancer cell lines. Thus,
increased sensitivity of primary malignant B cells to combined treatment may enlarge the therapeutic window of BH3-mimetic drugs for the treatment of B-cell malignancies. These findings can be exploited, possibly using combinations of novel BH3-mimetics, in therapeutic strategies targeting malignant B cells.

Materials and Methods

Tonsils, CLL cells and flow cytometry. Tonsils were obtained from patients undergoing tonsillectomy for chronic tonsillitis. The tonsillar tissue was cut into small pieces and forced through a cell strainer to generate single-cell suspensions. Single-cell suspensions were stained with the following antibodies: anti-CD19 (HIB19), anti-CD3 (UCHT1), anti-IgD (IA6-2), anti-CD38 (HB7) and anti-CXCR4 (12G5). Stained cells were analyzed on a FACScanto II or LSRFortessa cytometer (Beckton Dickinson (BD) Biosciences, San Jose, CA, USA). B-cell populations were sorted using a FACScanto II cytometer to a purity of 98%. CLL cells were obtained and cryopreserved as previously described.33 The study was approved by the medical ethics committee at the Academic Medical Center and written informed consent was obtained in accordance with the Declaration of Helsinki, Eucanada). CD5 and CD19 (number 4676; Cell Signaling, Biol) (catalog on leukemic cells was assessed by flow cytometry (FACScanto; BD Biosciences). CLL samples included in this study contained 81–99% CD5+CD19+ cells. Data in Figure 5b represents CLL cells from three patients (two with unmaturated and one with mutated IgVH gene sequences) where two patients were untreated before sampling and one patient was treated with fludarabine, cyclophosphamide and rituximab (FCR). Data in Figure 5c represents CLL cells from nine patients (four with unmaturated and five with mutated IgVH gene sequences) where seven patients were untreated, one patient was treated with FCR and one patient was treated with chlorambucil, cyclosporin, prednisolone and rituximab.

MLPA and qPCR. Total ribonucleic acid (RNA) for reverse transcriptase multiplex ligation-dependent probe amplification (RTMLPA) or quantitative real time PCR was extracted using an RNA miniprep kit (Sigma, St. Louis, MO, USA). RT-MLPA procedure was performed as previously described.34 qPCR was performed with Fast SYBR Green Master Mix on a StepOne Plus machine (Life Technologies, Netherlands) were used as secondary antibodies. anti-rabbit IgG or IRDye 800 donkey anti-goat IgG (Westburg, Leusden, The Netherlands Cancer Institute, Amsterdam, The Netherlands. IRDye 680 donkey antibody (catalog number T3605, ThermoFisher). Specific apoptosis was calculated by measuring the altered percentage of TOPRO3+ (live) cells within indicated B-cell populations, compared with untreated cells and is defined as (% cell death in treated cells) − (% cell death in medium control) × 100.

Statistical analysis. Statistical significance was determined using a two-tailed Student's t-test. P-values < 0.05 were considered statistically significant.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgments

We thank the facilities of our institute, and particularly B Noohink and T van Capel for flow cytometric cell sorting, the department of Otorhinolaryngology for donation of tonsils as leftover material after tonsillectomies and FM Wensveen and MHJ van Oers for critical reading of the manuscript. We are grateful to D Luijks for technical assistance with the MLPA experiments and to JP Medema and CD Zimberlin for the use of WEHI-539. This work was supported by a ZonMW-VENI grant (Number 91614046) to VP.

1. Czaban PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15: 49–63.
2. Peperzak V, Vikstrom IB, Tarlinton DM. Through a glass less darkly: apoptosis and the germlinal center response to antigen. Immunol Rev 2012; 247: 103–117.
3. Sours AJ, Levenson JD, Boghaert EH, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202–208.
4. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumor cell survival. Nature 2010; 463: 103–107.
5. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vivo and in vitro chemoresponses. Blood 1998; 91: 3379–3389.
6. Klippen S, Autio R, Ojala K, Bucher E, Sara H, Kilpinen S et al. Potent and selective small-molecule BCL-2 inhibitors demonstrate on-target cancer cell killing as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis 2015; 6: e1590.
7. Lessene G, Czaban PE, Sleeb BE, Zabol K, Lowes KN, Adams JM et al. Structure-guided design of a selective BCL-XL inhibitor. Nat Chem Biol 2013; 9: 389–397.
8. Küppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5: 251–262.
9. Krajewska S, Krajewska M, Shalbaky A, Wang HG, ilee S, Feng L et al. Immunohistochiometric analysis of in vivo patterns of Bcl-X expression. Cancer Res 1994; 54: 5551–5507.
10. Krajewska S, Bodo S, Gascoigne R, Bresan K, Krajewska M, Reed JC. Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol 1994; 145: 515–525.
Role of pro-survival proteins in human B cells

V Peperzak et al

12. Tuscano JM, Drewy KM, Riva A, Pena J, Thompson CB, Kehrl JH. Bcl-x rather than Bcl-2 mediates CD40-dependent centrocyte survival in the germinal center. Blood 1996; 88: 1359–1364.
13. Vikstrom I, Carotta S, Luthke Y, Peperzak V, Jost PJ, Glaser S et al. McI-1 is essential for germinal center formation and B cell memory. Science 2010; 330: 1095–1099.
14. Victora GD, Dominguez-Sola D, Holmes AB, Deroubaix S, Dalla-Favera R, Nussenzweig MC. Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood 2012; 120: 2240–2248.
15. Del Gairo Moore V, Letai A. BH3 profiling—measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett 2013; 322: 202–205.
16. Lopez J, Bessou M, Riley JS, Giampazolias E, Todt F, Rocheqüe T et al. Mito-priming as a method to engineer Bcl-2 addiction. Nat Commun 2016; 7: 10538.
17. Tijssen R, Sijger R, Weller K, van Noesel CJ, van Oers MH. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Hematologica 2015; 100: e306–e309.
18. Mojsa B, Lasso I, Desagher S. Mcl-1 ubiquitination: unique regulation of an essential survival protein. Cells 2014; 3: 418–437.
19. Khall I, Cambier JC, Striolochnjuk MAJ. B cell receptor signal transduction in the GC is short-conformed by high phosphatase activity. Science 2012; 336: 1178–1181.
20. Roberts AW, Davids MS, Pagel JM, Kahl BS, Pwuda SD, Gerogeto JF et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 2016; 374: 311–322.
21. Hallaert DY, Jaspers A, van Noesel CJ, van Oers MH, Kater AP, Eldering E et al. c-Abl kinase catalyses the polyubiquitination of Mcl-1 and regulates apoptosis. N Engl J Med 2016; 374: 1475–1486.
22. Delbridge ARD, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ 2015; 22: 1071–1080.
23. Zhong Q, Gao W, Du F, Wang X, Mule/APF-BP1, a BH3 only E3 ubiquitin ligase, catalyses the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005; 121: 1085–1096.
24. Okamoto T, Couttas L, Metcalf D, van Delft MF, Glaser SP, Takiguchi M et al. Sensitivity to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Hematologica 2015; 100: e306–e309.
25. Tijssen R, Sijger R, Weller K, van Noesel CJ, van Oers MH. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Hematologica 2015; 100: e306–e309.
26. Okamoto T, Coultas L, Metcalf D, van Delft MF, Glaser SP, Takiguchi M et al. Sensitivity to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Hematologica 2015; 100: e306–e309.